TRANSLOCATION RENAL CELL CARCINOMA
Clinical trials for TRANSLOCATION RENAL CELL CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new TRANSLOCATION RENAL CELL CARCINOMA trials appear
Sign up with your email to follow new studies for TRANSLOCATION RENAL CELL CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug cocktail aims to fight kidney cancer when immunotherapy fails
Disease control Recruiting nowThis study tests whether combining two oral drugs, abemaciclib and cabozantinib, is safe and effective for people with advanced clear cell or translocation kidney cancer that has already been treated with immunotherapy. The trial has two phases: first, finding the best dose with …
Matched conditions: TRANSLOCATION RENAL CELL CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New hope for rare cancers: immunotherapy drug targets tumors regardless of origin
Disease control Recruiting nowThis study tests the drug nivolumab in people with advanced rare cancers that have a specific marker (PD-L1). The goal is to see if the drug can shrink or control the tumors when other treatments have stopped working. Up to 28 adults will receive treatment for up to 12 months, an…
Matched conditions: TRANSLOCATION RENAL CELL CARCINOMA
Phase: PHASE2 • Sponsor: Instituto do Cancer do Estado de São Paulo • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
New cocktail of three drugs shows promise for tough kidney cancers
Disease control Recruiting nowThis phase 2 study is testing whether a combination of three drugs—sasanlimab, palbociclib, and axitinib—can shrink tumors or slow the growth of advanced kidney cancer. The trial will enroll 25 adults with clear cell or translocation renal cell carcinoma that has spread. Research…
Matched conditions: TRANSLOCATION RENAL CELL CARCINOMA
Phase: PHASE2 • Sponsor: Stephanie Berg • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC